Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium
- PMID: 20231535
- PMCID: PMC2861278
- DOI: 10.1161/CIRCULATIONAHA.109.869156
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium
Erratum in
- Circulation.2010 Jul 20;122(3):e399
Abstract
Background: Plasma levels of coagulation factors VII (FVII), VIII (FVIII), and von Willebrand factor (vWF) influence risk of hemorrhage and thrombosis. We conducted genome-wide association studies to identify new loci associated with plasma levels.
Methods and results: The setting of the study included 5 community-based studies for discovery comprising 23 608 European-ancestry participants: Atherosclerosis Risk In Communities Study, Cardiovascular Health Study, British 1958 Birth Cohort, Framingham Heart Study, and Rotterdam Study. All subjects had genome-wide single-nucleotide polymorphism (SNP) scans and at least 1 phenotype measured: FVII activity/antigen, FVIII activity, and vWF antigen. Each study used its genotype data to impute to HapMap SNPs and independently conducted association analyses of hemostasis measures using an additive genetic model. Study findings were combined by meta-analysis. Replication was conducted in 7604 participants not in the discovery cohort. For FVII, 305 SNPs exceeded the genome-wide significance threshold of 5.0x10(-8) and comprised 5 loci on 5 chromosomes: 2p23 (smallest P value 6.2x10(-24)), 4q25 (3.6x10(-12)), 11q12 (2.0x10(-10)), 13q34 (9.0x10(-259)), and 20q11.2 (5.7x10(-37)). Loci were within or near genes, including 4 new candidate genes and F7 (13q34). For vWF, 400 SNPs exceeded the threshold and marked 8 loci on 6 chromosomes: 6q24 (1.2x10(-22)), 8p21 (1.3x10(-16)), 9q34 (<5.0x10(-324)), 12p13 (1.7x10(-32)), 12q23 (7.3x10(-10)), 12q24.3 (3.8x10(-11)), 14q32 (2.3x10(-10)), and 19p13.2 (1.3x10(-9)). All loci were within genes, including 6 new candidate genes, as well as ABO (9q34) and VWF (12p13). For FVIII, 5 loci were identified and overlapped vWF findings. Nine of the 10 new findings were replicated.
Conclusions: New genetic associations were discovered outside previously known biological pathways and may point to novel prevention and treatment targets of hemostasis disorders.
Conflict of interest statement
Disclosures: No author has a real or perceived conflict of interest to report for this manuscript except James B. Meigs who reports receiving grant support from Sanofi-Aventis and GlaxoSmithKline, and serving as a consultant/advisor to Interleukin Genetics and Eli Lilly.
Figures



References
-
- Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost. 2001;86:366–373. - PubMed
-
- Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005;112:3080–3087. - PubMed
-
- Folsom AR, Cushman M, Heckbert SR, Ohira T, Rasmussen-Torvik L, Tsai MY. Factor VII coagulant activity, factor VII -670A/C and -402G/A polymorphisms, and risk of venous thromboembolism. J Thromb Haemost. 2007;5:1674–1678. - PubMed
-
- Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–155. - PubMed
-
- Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117:1449–1459. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01-HL-086694/HL/NHLBI NIH HHS/United States
- N01 HC055019/HL/NHLBI NIH HHS/United States
- N01 HC085081/HC/NHLBI NIH HHS/United States
- N01-HC-85086/HC/NHLBI NIH HHS/United States
- G20234/2/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- N01 HC025195/HL/NHLBI NIH HHS/United States
- DK063491/DK/NIDDK NIH HHS/United States
- N01 HC035129/HC/NHLBI NIH HHS/United States
- N01 HC055016/HC/NHLBI NIH HHS/United States
- M01-RR00425/RR/NCRR NIH HHS/United States
- N02-HL-6-4278/HL/NHLBI NIH HHS/United States
- N01-HC-25195/HC/NHLBI NIH HHS/United States
- CZB/4/710/CSO_/Chief Scientist Office/United Kingdom
- N01 HC055022/HC/NHLBI NIH HHS/United States
- HL073410/HL/NHLBI NIH HHS/United States
- N01 HC085086/HC/NHLBI NIH HHS/United States
- R01 HL095080/HL/NHLBI NIH HHS/United States
- N01 HC055016/HL/NHLBI NIH HHS/United States
- UL1 RR025005/RR/NCRR NIH HHS/United States
- UL1-RR-025005/RR/NCRR NIH HHS/United States
- G0000934/MRC_/Medical Research Council/United Kingdom
- U01 HL080295/HL/NHLBI NIH HHS/United States
- N02 HL064278/HL/NHLBI NIH HHS/United States
- N01 HC075150/HC/NHLBI NIH HHS/United States
- N01-HC-55022/HC/NHLBI NIH HHS/United States
- N01-HC-85081/HC/NHLBI NIH HHS/United States
- R01 HL059367/HL/NHLBI NIH HHS/United States
- N01 HC055021/HL/NHLBI NIH HHS/United States
- 068545/Z/02/WT_/Wellcome Trust/United Kingdom
- MC_U127561128/MRC_/Medical Research Council/United Kingdom
- R01-HL-087641/HL/NHLBI NIH HHS/United States
- N01 HC015103/HC/NHLBI NIH HHS/United States
- N01 HC085086/HL/NHLBI NIH HHS/United States
- N01-HC-55016/HC/NHLBI NIH HHS/United States
- N01 HC085083/HC/NHLBI NIH HHS/United States
- N01 HC055018/HC/NHLBI NIH HHS/United States
- N01 HC025195/HC/NHLBI NIH HHS/United States
- R01 HL086694/HL/NHLBI NIH HHS/United States
- DH_/Department of Health/United Kingdom
- N01 HC085085/HC/NHLBI NIH HHS/United States
- N01 HC055015/HL/NHLBI NIH HHS/United States
- R01 HL087652/HL/NHLBI NIH HHS/United States
- N01-HC-55021/HC/NHLBI NIH HHS/United States
- HHSN268200625226C/PHS HHS/United States
- U01 HG004402/HG/NHGRI NIH HHS/United States
- N01 HC055020/HL/NHLBI NIH HHS/United States
- R01 DK033651/DK/NIDDK NIH HHS/United States
- N01 HC085082/HC/NHLBI NIH HHS/United States
- N01-HC-85082/HC/NHLBI NIH HHS/United States
- R01-HL-59367/HL/NHLBI NIH HHS/United States
- N01 HC055019/HC/NHLBI NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- N01 HC085080/HC/NHLBI NIH HHS/United States
- N01-HC-55019/HC/NHLBI NIH HHS/United States
- N01-HC-55015/HC/NHLBI NIH HHS/United States
- N01 HC055222/HL/NHLBI NIH HHS/United States
- N01 HC055222/HC/NHLBI NIH HHS/United States
- R01 HL 087652/HL/NHLBI NIH HHS/United States
- N01-HC-55222/HC/NHLBI NIH HHS/United States
- 068545/WT_/Wellcome Trust/United Kingdom
- K24 DK080140/DK/NIDDK NIH HHS/United States
- N01 HC085079/HL/NHLBI NIH HHS/United States
- N01-HC-85083/HC/NHLBI NIH HHS/United States
- N01-HC-75150/HC/NHLBI NIH HHS/United States
- 079996/WT_/Wellcome Trust/United Kingdom
- N01-HC-55020/HC/NHLBI NIH HHS/United States
- N01-HC-85080/HC/NHLBI NIH HHS/United States
- G0000934(68341)/MRC_/Medical Research Council/United Kingdom
- 091746/WT_/Wellcome Trust/United Kingdom
- N01 HC055015/HC/NHLBI NIH HHS/United States
- N01 HC055021/HC/NHLBI NIH HHS/United States
- N01 HC055018/HL/NHLBI NIH HHS/United States
- M01 RR000425/RR/NCRR NIH HHS/United States
- HL095080/HL/NHLBI NIH HHS/United States
- N01 HC085084/HC/NHLBI NIH HHS/United States
- G20234/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- N01-HC-85079/HC/NHLBI NIH HHS/United States
- N01 HC055022/HL/NHLBI NIH HHS/United States
- N01 HC055020/HC/NHLBI NIH HHS/United States
- MC_QA137934/MRC_/Medical Research Council/United Kingdom
- N01 HC085079/HC/NHLBI NIH HHS/United States
- N01 HC075150/HL/NHLBI NIH HHS/United States
- N01-HC-55018/HC/NHLBI NIH HHS/United States
- R01 HL087641/HL/NHLBI NIH HHS/United States
- U01-HG-004402/HG/NHGRI NIH HHS/United States
- R01 HL073410/HL/NHLBI NIH HHS/United States
- N01 HC045133/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous